The global
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market was
valued at approximately US$ 2.9 Bn in 2016 is projected to register cumulative
annual growth rate (CAGR) of over 3.2% from 2017 to 2025, according to a new
report published by Transparency Market Research titled “Methicillin-resistant
Staphylococcus Aureus (MRSA) Drugs Market – Global Industry Analysis, Size,
Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that
rising incidence of the development of antibiotic resistant strains among all
age groups are likely to spur the demand of MRSA Drugs in the coming years
(2017 to 2025). As key players introduce novel anti-MRSA agents in developed
markets such a North America and Europe, these regions are likely to account
for dominating share of the global MRSA Drugs market. Established presence
& wide distribution networks of major players and growing market
penetration of emerging players are likely to boost growth of Asia Pacific MRSA
Drugs market at a CAGR of around 3.7% from 2017 to 2025.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1315
Development of Treatment-Emergent Resistance in MRSA-Infected Patients to
Restrain the Growth of MRSA Drugs
According to CDC, around 33% of the people carry
staphylococcus aureus, also known as staph, in their nose. But over the
decades, few strains of staph such as MRSA (Methicillin-resistant
Staphylococcus Aureus) have become resistant to some antibiotics that once
destroyed it. MRSA strains are thus a type of staph that are resistant to
beta-lactam antibiotic called methicillin. Around 1% of the population carrying
staphylococcus aureus on their nose or skin are infected by MRSA. However,
increased practice of prescribing antibiotics, 50% of which are unnecessary and
inappropriate, is responsible to give rise to treatment-emergent resistance in
MRSA-infected patients. According to the CDC, resistance to tigecycline and
vancomycin, which are the effective and potent therapeutic options for severe
MRSA infection, has emerged. Such treatment-emergent resistant strains
developing in the MRSA-infected patients are expected to restrain the growth of
MRSA drugs market during the forecast period.
Request for Analysis of COVID-19
Impact on Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1315
Lipopeptide drug class to lose the market share
The report offers detailed segmentation of global
MRSA drugs market on the basis of drug class, route of administration, and
distribution channel. Among the drug class, lipopeptide is poised to account
for leading share of the global market during the forecast period from 2017 to
2025. However, the segment is expected to lose its market share from 31.6% in
2016 to 30.5% by the end of 2025, owing to the loss of patent exclusivity for
daptomycin in 2016, and emergence of generic drug molecules in lipopeptide drug
class. Key pharmaceuticals companies such as Pfizer, Inc. involved in the
manufacturing of oxazolidinones against MRSA infection, and their strong
positioning in the global MRSA drugs market is likely to get boost the growth
of oxazolidinone segment during the forecast period.
Oral to Be the Most Promising Route of Administration to Invest In
Various route of administration offered in the
report are oral and parenteral. Parenteral route of administration accounted
for highest market share of 72.2% in 2016, due to the increased investment in
the pharmaceutical sector by key antibiotics manufacturers to boost the
production of intravenous anti-MRSA antibiotics. Oral route of administration
is expected to get a boost in terms of revenue by 2025, which is attributable
to the key companies involved in the R&D of anti-MRSA vaccines.
Buy Methicillin-resistant
Staphylococcus Aureus (MRSA) Drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=1315<ype=S
Asia Pacific to Register Exponential Growth Rate and Offer Huge Incremental
Opportunity
Geographically, the global MRSA drugs market is
segmented into five major regions, which are North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. In 2016, North America
accounted for the highest market share in terms of revenue, which is
attributable to the investments by U.S. based key players in the R&D of
screening tools for MRSA infection. Europe is the second most prominent region
in the global MRSA drugs market, which is projected to grow during the forecast
period, due to research grants by the public & private players in the
European countries to propel the R&D of anti-MRSA antibiotics. However,
huge patient pool in the countries of China and India, and uncontrolled
consumption of antibiotics in India are estimated to fuel the growth of MRSA
drugs market in Asia Pacific with relatively significant CAGR of 3.7% during
2017-2025.
Ask For Discount:
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1315
Key Players such as Merck & Co., Inc., and Pfizer, Inc. are Likely to
Continue to Lead the Global MRSA Drugs Market
The prominent players operating in the global MRSA
Drugs Market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance
Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc. Investing in the
R&D and clinical trials of unique drug molecules in topical dosage form is
the major strategy being adopted by key manufacturers to stay ahead in the
rising competition.
Browse more Market Reports:
Assistive Listening Devices Market:
https://www.transparencymarketresearch.com/assistive-listening-devices-market.html
Portable Oxygen Concentrators Market:
https://www.transparencymarketresearch.com/portable-oxygen-concentrators.html
Aromatherapy Market:
https://www.transparencymarketresearch.com/aromatherapy-market.html
About Us:
Transparency Market Researchis a global market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision
makers. Our experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather, and
analyse information. Now avail flexible Research Subscriptions, and access
Research multi-format through downloadable databooks, infographics, charts,
interactive playbook for data visualization and full reports through MarketNgage,
the unified market intelligence engine. Sign Up for
a 7 day free trial!
Contact Us
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
The Wall